Increased Absorption of Palmitoylethanolamide Using a Novel Dispersion Technology System (LipiSperse)
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 28 healthy volunteers aged 18 to 30, in two parallel groups
- Dose used in the study
- A single 300 mg dose: palmitoylethanolamide with the LipiSperse dispersion system (Levagen+) or standard palmitoylethanolamide
- Duration
- Blood samples over 4 hours
- What was measured
- Plasma palmitoylethanolamide over time, as area under the curve and peak concentration
What the authors reported
The authors reported that the dispersion form gave an area under the curve 1.75 times that of the standard form (p < 0.05), with a higher peak rise (11.12 against 7.96 pmol/mL) and an earlier peak (105 against 125 minutes). No adverse events were reported.
Limits of this study
The authors state that 4 hours of sampling was too short, because plasma levels had not returned to baseline. The design compared two separate groups of 14, not the same people on both products. The study compares a dispersion form with plain powder. It does not compare it with micronised forms. It was funded by Pharmako Biotechnologies and Gencor Pacific, which make the product.
Source
doi:10.36648/nutraceuticals.5.2.3
Entry checked against the full text at the publisher (Insight Medical Publishing) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.